# Optical Coherence Tomography for Drug Eluting Stent Safety

> **NCT00693030** · PHASE4 · UNKNOWN · sponsor: **A.O. Ospedale Papa Giovanni XXIII** · enrollment: 77 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)
- **DEVICE:** paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)
- **DEVICE:** zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)
- **DEVICE:** Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)

## Key facts

- **NCT ID:** NCT00693030
- **Lead sponsor:** A.O. Ospedale Papa Giovanni XXIII
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-08
- **Primary completion:** 2008-06
- **Final completion:** 2008-12
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2008-06-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693030, "Optical Coherence Tomography for Drug Eluting Stent Safety". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00693030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*